221 CRESCENT STREET, WALTHAM, MA
Spyre Therapeutics Enters Underwriting Agreement for $275 Million Offering
Spyre Therapeutics Reports Preliminary Cash Position of $486.2 Million
Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Investor Presentation
Shareholder votes
Reports First Quarter 2025 Financial Results and Provides Corporate Update
Annual Report to Security Holders
Changing the Company's Accountant
Q2
Q1
Amended Quarterly Report
Q3
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
PRER14A
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement